JPMorgan Chase & Co. purchased a new stake in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 47,792 shares of the company's stock, valued at approximately $786,000. JPMorgan Chase & Co. owned approximately 0.09% of Upstream Bio as of its most recent filing with the SEC.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Corebridge Financial Inc. bought a new stake in Upstream Bio in the fourth quarter worth approximately $142,000. Charles Schwab Investment Management Inc. bought a new stake in Upstream Bio in the fourth quarter worth $2,225,000. US Bancorp DE acquired a new position in Upstream Bio during the fourth quarter worth $27,000. Bank of New York Mellon Corp bought a new position in Upstream Bio during the fourth quarter valued at about $607,000. Finally, Rhumbline Advisers acquired a new stake in shares of Upstream Bio in the fourth quarter worth about $275,000.
Upstream Bio Stock Performance
Shares of UPB traded down $0.36 during trading hours on Friday, hitting $8.64. 484,378 shares of the company were exchanged, compared to its average volume of 324,226. The firm's 50 day moving average is $7.96 and its 200-day moving average is $14.07. Upstream Bio, Inc. has a 52 week low of $5.14 and a 52 week high of $29.46.
Upstream Bio Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Recommended Stories
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
